All Stories

‘We cannot stay silent’: Novo Nordisk flags dangers of compounded GLP-1s following Hims & Hers Super Bowl ad

Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its weight-loss program, which offers access to compounded semaglutide. Now, semaglutide maker Novo Nordisk is chiming in.

Feb 12, 2025 - 21:43
 0
‘We cannot stay silent’: Novo Nordisk flags dangers of compounded GLP-1s following Hims & Hers Super Bowl ad
Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its weight-loss program, which offers access to compounded semaglutide. Now, semaglutide maker Novo Nordisk is chiming in.
Read More

Tags:

Previous Article

Hot Topic, AllCampus partner for employee degree benefits

Next Article

Recycling Lithium-Ion Batteries Offers Benefits Over Mining Virgin Metals

Related Posts

Pfizer's blockbuster ADC Adcetris nabs FDA approval to treat large B-cell lymphoma

Pfizer's blockbuster ADC Adcetris nabs FDA approval to ...

Feb 12, 2025  0

Schwarzenegger spins ‘Terminator’ catchphrase for Zimmer Biomet’s big marketing push

Schwarzenegger spins ‘Terminator’ catchphrase for Zimme...

Feb 26, 2025  0

Merck KGaA's EMD Serono taps Selma Blair to join long-running campaign for MS drug Mavenclad

Merck KGaA's EMD Serono taps Selma Blair to join long-r...

Feb 20, 2025  0